Familial Hypercholesterolemia clinical trials

Explore recruiting familial hypercholesterolemia clinical trials.

Recruiting familial hypercholesterolemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Familial Hypercholesterolemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Reassessment of statin-associated musscle symptoms in adults with familial hypercholesterolemia: A phase IV randomized double-blinded n-of-1 crossover trial including periods with atorvastatin, placebo and no study treatment

Norway

Therapeutic use (Phase IV) EU CTIS Study details

Study 1002-041: An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) with Heterozygous Familial Hypercholesterolemia

Germany, Netherlands, Denmark, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

Netherlands, Denmark, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (2 to less than 12 years) with homozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-19)

Spain, Greece, Germany, Netherlands, France, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (6 to less than 12 years) with heterozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-20)

Czechia, Portugal, Netherlands, France, Belgium, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Familial Hypercholesterolemia trials by city

Familial Hypercholesterolemia in Toronto Familial Hypercholesterolemia in Vancouver Familial Hypercholesterolemia in Montreal Familial Hypercholesterolemia in Calgary Familial Hypercholesterolemia in Edmonton Familial Hypercholesterolemia in Ottawa Familial Hypercholesterolemia in Winnipeg Familial Hypercholesterolemia in Quebec City Familial Hypercholesterolemia in Hamilton Familial Hypercholesterolemia in Kitchener Familial Hypercholesterolemia in London Familial Hypercholesterolemia in Halifax Familial Hypercholesterolemia in New York Familial Hypercholesterolemia in Los Angeles Familial Hypercholesterolemia in Chicago Familial Hypercholesterolemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease